Company Filing History:
Years Active: 2000-2002
Title: Innovations of Alfons Valera Abril in Gene Therapy
Introduction
Alfons Valera Abril is a notable inventor based in Cerdanyola, Spain. He has made significant contributions to the field of gene therapy, particularly in the treatment of diabetes. With a total of two patents to his name, his work focuses on innovative approaches to insulin expression.
Latest Patents
One of Alfons Valera Abril's latest patents is a chimeric gene utilizing the gene or cDNA of insulin, specifically designed for gene therapy in diabetes. This chimeric gene is directed by a promoter or a fusion of promoters that are preferably regulable and activated by the diabetic process. The gene is obtained by fusing the human insulin gene to the promoter of PEPCK (P-enolpiruvate carboxiquinasa). The promoter fragment, ranging from -460 bp to +73 bp, is fused to the flank zone of the human insulin gene, which spans from -170 bp to +1. The human insulin gene comprises two coding exons, E1 and E2, along with two introns, A and B. This invention also includes an expression vector that facilitates the expression of insulin in cells other than the β-cells of the pancreas, as well as a transgenic animal that expresses the chimeric gene. This innovation is particularly aimed at advancing gene therapy for diabetes.
Career Highlights
Alfons Valera Abril is affiliated with the Universitat Autonoma De Barcelona, where he continues to engage in groundbreaking research. His work has garnered attention for its potential to revolutionize diabetes treatment through genetic engineering.
Collaborations
Alfons Valera Abril collaborates with Fatima Bosch Tubert, a fellow researcher in the field. Their partnership exemplifies the collaborative spirit of scientific inquiry and innovation.
Conclusion
Alfons Valera Abril's contributions to gene therapy, particularly in diabetes treatment, highlight the importance of innovation in medical science. His patents reflect a commitment to advancing healthcare through research and development.